Patient characteristics. AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin’s lymphoma; ALL, acute lymphoblastic leukemia; MDS, myelodyplastic syndrome; NHL, non-Hodgkin’s lymphoma; PBSCs, peripheral blood stem cells; BM, bone marrow; MMF, mycophenolate mofetil.
| Cohort 1 | Cohort 2 | ||||||
| No chronic GVHD (n = 14) | Chronic GVHD (n = 31) | P | IL-2–treated chronic GVHD (n = 14) | ||||
| n | % | n | % | n | % | ||
| Age at SCT, median (range) | 44 (27–52) | 48 (20–63) | 0.31 | ||||
| M/F | 10/4 | 19/12 | 0.06 | 5/9 | |||
| Diagnosis | 0.59 | ||||||
| AML | 6 | 42.9 | 15 | 48.4 | 5 | 35.7 | |
| CLL | 1 | 7.1 | 4 | 12.9 | 5 | 35.7 | |
| CML | 2 | 14.3 | 4 | 12.9 | 1 | 7.1 | |
| HL | 0 | 0 | 1 | 3.2 | 1 | 7.1 | |
| ALL | 3 | 21.4 | 2 | 6.5 | |||
| MDS | 0 | 0 | 3 | 9.7 | 1 | 7.1 | |
| NHL | 2 | 14.3 | 2 | 6.5 | 1 | 7.1 | |
| Conditioning regimen | 0.3 | ||||||
| Myeloablative | 14 | 100 | 26 | 83.9 | 7 | 50 | |
| Nonmyeloablative | 0 | 0 | 5 | 16.1 | 7 | 50 | |
| Stem cell source | 1 | ||||||
| PBSCs | 14 | 100 | 30 | 96.8 | 13 | 92.9 | |
| BM and PBSCs | 0 | 0 | 1 | 3.2 | 1 | 7.1 | |
| Donor type | 0.04 | ||||||
| Matched-related | 12 | 85.7 | 14 | 45.2 | 4 | 28.6 | |
| Matched-unrelated | 2 | 14.3 | 14 | 45.2 | 7 | 50 | |
| Mismatched- unrelated | 0 | 0 | 3 | 9.7 | 3 | 21.4 | |
| Acute GVHD prophylaxis | 0.33 | ||||||
| Sirolimus- containing | 10 | 71.4 | 16 | 51.6 | 9 | 64.3 | |
| No sirolimus- containing | 4 | 28.6 | 15 | 48.4 | 5 | 35.7 | |
| Acute GVHD | 0.02 | ||||||
| Grade 2–4 | 1 | 7.1 | 14 | 45.2 | 5 | 35.7 | |
| Days to sample collection | |||||||
| Median | 2168 | 1020 | 0.1 | ||||
| Range | 440–2952 | 412–2807 | |||||
| Days to chronic GVHD | |||||||
| Median (range) | 263 (125–927) | 269 (130–483) | |||||
| Severity of chronic GVHD | |||||||
| Mild | 9 | 29 | |||||
| Moderate | 8 | 25.8 | |||||
| Severe | 14 | 45.2 | |||||
| Immunosuppressive therapy* | |||||||
| Prednisone | 0.0001 | ||||||
| 0 mg | 12 | 85.7 | 6 | 19.4 | 1 | 7.1 | |
| 0 to ≤10 mg | 2 | 14.3 | 10 | 32.3 | 2 | 14.2 | |
| >10 mg | 0 | 0.0 | 15 | 48.4 | 11 | 78.6 | |
| Sirolimus | 0.09 | ||||||
| 0 mg | 13 | 92.9 | 19 | 61.3 | 8 | 71 | |
| 0 to ≤1 mg | 1 | 7.1 | 7 | 22.6 | 2 | 14.2 | |
| >1 mg | 0 | 0.0 | 5 | 16.1 | 4 | 28.4 | |
| Tacrolimus | 0.04 | ||||||
| 0 mg | 14 | 100.0 | 20 | 64.5 | 9 | 64.3 | |
| 0 to ≤1 mg | 0 | 0.0 | 6 | 19.4 | 2 | 14.2 | |
| >1 mg | 0 | 0.0 | 5 | 16.1 | 3 | 21.3 | |
| MMF | 0.007 | ||||||
| 0 mg | 14 | 100.0 | 16 | 51.6 | 4 | 28.4 | |
| 0 to ≤500 mg | 0 | 0.0 | 3 | 9.7 | 1 | 7.1 | |
| >500 mg | 0 | 0.0 | 12 | 38.7 | 9 | 64.3 | |
*In cohort 1 patients, immunosuppressive therapies when samples were collected are shown. In cohort 2 patients, immunosuppressive therapies at the initiation of low-dose IL-2 therapy are shown.